header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FIG-150506-32
Sasore et al., 2014 - Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo. PLoS One   9:e105280 Full text @ PLoS One
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Gene:
Fish:
Condition:
Anatomical Term:
Stage: Day 5
PHENOTYPE:
Fish:
Condition:
Observed In:
Stage: Day 5

Fig. 5

Qualitative effects of PI3K/Akt/mTOR inhibitors on ocular angiogenesis.

Representative images demonstrating anti-angiogenic effects of PI3K/Akt/mTOR inhibitors on development of HV. 5 µM NVP-BEZ235 + Rapamycin (B), 5 µM LY294002 + NVP-BEZ235 (C) and 5 µM NVP-BEZ235 + PI103 (D) exhibited significant reductions in primary HV branch number compared to 0.1% DMSO-treated larvae (A). Small, but significant differences were observed in the number of primary branches and overall hyaloid vasculature patterning in 5 µM NVP-BEZ235, 5 µM LY294002, 5 µM Rapamycin and 5 µM -PI103-treated larvae (E-H) compared to control (A). Blue circles depict the optic nerve head. White arrows label primary HV branches emanating from the optic disc at the back of the lens. Red arrows indicate the lens orientation pointing in the direction from the optic disk to the lens. Scale bar 100 µm. N = 26-30.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
EGFP y1Tg control Day 5 hyaloid vessel IFL
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel IFL
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel IFL
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel IFL
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel IFL
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel IFL
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel IFL
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel IFL
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Day 5 hyaloid vessel sprouting angiogenesis decreased process quality, abnormal
Acknowledgments:
ZFIN wishes to thank the journal PLoS One for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ PLoS One